Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SePkLin study of personalized PK/PD-guided linezolid dosing in sepsis
2022-000144-30Phase 4Active
- Sponsor
- Instituto de Investigación Sanitaria de Santiago de Compostela
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of linezolid in sepsis and bacterial disease (2 arms), sponsored by Instituto de Investigación Sanitaria de Santiago de Compostela. Primary endpoint: Incidence of thrombocytopenia. Started Mar 2022; status: active.
02
Drugs
linezolid
03
Conditions
sepsisbacterial disease
Beyond the preview
Go deeper on 2022-000144-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000144-30.